دورية أكاديمية
Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey
| العنوان: | Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey |
|---|---|
| المؤلفون: | Cattaneo, Chiara, El-Ashwah, Shaimaa, Itri, Federico, Weinbergerova, Barbora, Jiménez, Moraima, Salmanton-García, Jon, Marchesi, Francesco, Cabirta, Alba |
| المساهمون: | Institut Català de la Salut, Cattaneo C Hematology Unit, ASST-Spedali Civili, Brescia, Italy. Salmanton-García J University of Cologne, Faculty of Medicine, University Hospital Cologne, Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany. University of Cologne, Faculty of Medicine, University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center for Medical Mycology (ECMM), Cologne, Germany. Marchesi F Hematology and Stem Cell Transplant Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy. El-Ashwah S Oncology Center, Mansoura University, Mansoura, Egypt. Itri F San Luigi Gonzaga Hospital, Orbassano, Italy. Weinbergerová B Masaryk University and University Hospital Brno—Department of Internal Medicine, Hematology and Oncology, Brno, Czech Republic. Cabirta A Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Jiménez M Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus |
| المصدر: | Scientia |
| بيانات النشر: | MDPI |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | COVID-19 (Malaltia) - Diagnòstic, Sang - Càncer - Diagnòstic, Sang - Càncer - Tractament, Avaluació de resultats (Assistència sanitària), DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections, DISEASES::Neoplasms::Neoplasms by Site::Hematologic Neoplasms, Other subheadings::Other subheadings::Other subheadings::/drug therapy, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome, ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias hematológicas, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento |
| الوصف: | COVID-19; Outcome; Prognostic factors ; COVID-19; Resultado; Factores pronósticos ; COVID-19; Resultat; Factors pronòstics ; Background: The outcome of patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 is unknown and there are no specific treatment guidelines. Methods: We describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022. Results: Acute leukaemia and lymphoma were the most frequent HM (35.8% and 35.1%, respectively). Overall, 343 (76.2%) patients received treatment for HM, which was delayed for longer than one month since diagnosis in 57 (16.6%). An overall response rate was observed in 140 (40.8%) patients after the first line of treatment. After a median follow-up of 35 days, overall mortality was 177/450 (39.3%); 30-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004), either before and/or after COVID-19, or compared to patients receiving HM treatment at least after COVID-19 (15.2%, p < 0.001). Age, severe/critical COVID-19, ≥2 comorbidities, and lack of HM treatment were independent risk factors for mortality, whereas a lymphocyte count >500/mcl at COVID-19 onset was protective. Conclusions: HM treatment should be delivered as soon as possible for patients with simultaneous diagnosis of COVID-19 and HM requiring immediate therapy. ; EPICOVIDEHA has received funds from Optics COMMITTM (COVID-19 Unmet Medical Needs and Associated Research Extension) COVID-19 RFP program by GILEAD Science, United States (Project 2020-8223). |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| ردمك: | 978-0-00-887127-7 0-00-887127-2 |
| تدمد: | 2072-6694 |
| العلاقة: | Cancers;14(22); https://doi.org/10.3390/cancers14225530Test; Cattaneo C, Salmanton-García J, Marchesi F, El-Ashwah S, Itri F, Weinbergerová B, et al. Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey. Cancers. 2022 Nov 10;14(22):5530.; https://hdl.handle.net/11351/9664Test; 000887127200001 |
| DOI: | 10.3390/cancers14225530 |
| الإتاحة: | https://doi.org/10.3390/cancers14225530Test https://hdl.handle.net/11351/9664Test |
| حقوق: | Attribution 4.0 International ; http://creativecommons.org/licenses/by/4.0Test/ ; info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.47BEEBCB |
| قاعدة البيانات: | BASE |
Full Text Finder | ردمك: | 9780008871277 0008871272 |
|---|---|
| تدمد: | 20726694 |
| DOI: | 10.3390/cancers14225530 |